Croda International (LSE: CRDA), the FTSE 100 speciality chemicals group, has set out a three-year plan to lift growth, margins and returns after a period of destocking and reset. The 2025 results show real progress on the numbers investors track — alongside a large impairment that tells its own cautionary story.

The Quick Version

  • FY2025 sales were £1,699.4m, up 6.6% at constant currency, with adjusted operating profit of £295.3m.
  • Statutory IFRS profit fell sharply on non-cash impairments and provisions of roughly £185m, including a standby of the Lamar lipids facility in the US.
  • A new 2026-2028 framework targets 3-6% organic sales growth, an adjusted operating margin above 20% and return on invested capital above 10%.
  • Q1 2026 sales rose 1% at constant currency to £431m, with Consumer Care strength offsetting softer Life Sciences.
  • The dividend edged up to 111.0p for 2025, but the payout sits above policy while earnings rebuild.

What Croda Actually Does

Founded in 1925 and headquartered in East Yorkshire, Croda marked its centenary in 2025 with a reputation for high-value, science-led ingredients rather than commodity chemicals. It reports through three divisions: Consumer Care (beauty, skincare, fragrances, flavours, home care), Life Sciences (pharmaceutical, crop protection, seed enhancement, including drug-delivery lipid systems), and Industrial Specialities.

Why Croda Is Trying a Comeback Right Now

Like much of speciality chemicals, Croda was hit hard by widespread customer destocking in 2023-2024, weighing on volumes particularly in Consumer Care and crop-related markets. With its 24 February 2026 full-year results, management published a 2026-2028 financial framework setting explicit targets for growth, profitability, cash generation and returns — CEO Steve Foots described being 'encouraged by the early progress.'

The Numbers: Growth Returns, But So Does an Impairment

For the year ended 31 December 2025, sales were £1,699.4m, up 4.4% reported and 6.6% at constant currency. Adjusted operating profit rose 5.6% to £295.3m, with the margin edging up to 17.4%. Adjusted EPS rose 2.5% to 146.2p.

The statutory picture told a very different story: IFRS operating profit fell to £110.1m from £227.5m, with the gap reflecting non-cash adjusting items including impairments of about £107.3m, notably placing the Lamar lipids facility in the US on standby. By division, Consumer Care and Life Sciences each grew around 8% at constant currency, while Industrial Specialities declined about 2%.

The most recent Q1 2026 update (22 April 2026) showed group sales of £431m, up 1% at constant currency but down 2% reported. Consumer Care rose 4% on beauty actives and fragrances, while Life Sciences fell 3% on softer crop protection and pharma. Croda reaffirmed no change to full-year 2026 expectations.

Growth Drivers

Consumer Care and beauty actives remain the largest division and central to any recovery, with double-digit constant-currency growth reported in early 2026. Croda's Life Sciences lipid systems (used in vaccines and advanced therapies) saw a pandemic-driven surge followed by a sharp reset — the Lamar standby reflects that, though demand could recover if the nucleic-acid therapeutics pipeline develops as hoped. Crop protection and seed enhancement could benefit as the agrochemical cycle stabilises, though the soft Q1 2026 shows the recovery isn't yet secure. An internal transformation programme aims to simplify the business and support the framework's margin and cash targets.

The Dividend: Growing, But Stretched

Croda declared a total dividend of 111.0p for 2025, a small increase on 110.0p for 2024. The dividend is currently well covered on an adjusted basis (adjusted EPS of 146.2p) but stretched relative to depressed statutory earnings — the payout ratio has risen above Croda's stated 40-50% policy range while profits rebuild. Management frames this as temporary, but it's worth monitoring, and dividends are never guaranteed.

The 2026-2028 framework targets free-cash-flow-to-sales above 12% (from 9.5% in 2025) and return on invested capital above 10% (from 8.2%) — goals, not commitments.

Why Valuation Needs Care Here

Headline P/E ratios based on IFRS earnings of 44.4p look very high, reflecting the large non-cash impairment rather than the underlying run-rate. On adjusted EPS of 146.2p, the multiple is far lower — which is why the market tends to focus on adjusted measures. Croda has historically traded at a premium reflecting its differentiated portfolio and high margins; that premium has compressed through the downturn, which is part of what makes the recovery thesis debatable.

Risks Worth Weighing

Demand risk is most immediate — Croda's fortunes depend on customer ordering across beauty, pharmaceutical, agricultural and industrial markets, all volatile through the destocking cycle, and the soft Q1 2026 Life Sciences performance shows recovery is uneven. Execution risk applies to the ambitious 2026-2028 framework and transformation programme, and the 2025 impairment is a reminder that further write-downs are possible. The elevated payout ratio, raw-material and energy cost inflation, and significant currency exposure round out the picture.

What to Watch Next

Half-year 2026 results, scheduled for 28 July 2026, will show whether the modest Q1 momentum continued. Progress against the 2026-2028 framework — margin toward 20%-plus, free-cash-flow-to-sales toward 12%, ROIC above 10% — is the central story, alongside updates on the Lamar facility and any pharmaceutical lipid demand recovery.